Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:6841628.
doi: 10.1155/2016/6841628. Epub 2016 Jan 31.

Recent Advances in Antiviral Therapy for Chronic Hepatitis C

Akihiro Tamori  1 , Masaru Enomoto  1 , Norifumi Kawada  1
Affiliations
Review

Recent Advances in Antiviral Therapy for Chronic Hepatitis C

Akihiro Tamori et al. Mediators Inflamm. 2016.

Abstract

Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis. This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. DAA treatment failure and prognosis after DAA therapy are also discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment of HCV with DAAs that are approved or are going to be approved.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pearlman B. L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet Infectious Diseases. 2012;12(9):717–728. doi: 10.1016/s1473-3099(12)70060-9. - DOI - PubMed
    1. McHutchison J. G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061–1069. doi: 10.1053/gast.2002.35950. - DOI - PubMed
    1. Coppola N., Pisaturo M., Tonziello G., Sagnelli C., Sagnelli E., Angelillo I. F. Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infectious Diseases. 2012;12, article 357 doi: 10.1186/1471-2334-12-357. - DOI - PMC - PubMed
    1. Tamori A., Kioka K., Kurai O., et al. Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. Hepatology Research. 2011;41(12):1169–1177. doi: 10.1111/j.1872-034x.2011.00887.x. - DOI - PubMed
    1. Nishiguchi S., Enomoto H., Aizawa N., et al. Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of genotype 1b: a multicenter randomized trial, ReGIT-J study. Journal of Gastroenterology. 2014;49(3):492–501. doi: 10.1007/s00535-013-0785-2. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources